{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:46:52Z","timestamp":1762904812015,"version":"3.45.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":230,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jtauto.2021.100114","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T14:21:37Z","timestamp":1629382897000},"page":"100114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab"],"prefix":"10.1016","volume":"4","author":[{"given":"Lisa C.","family":"Plymate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell P.","family":"Krist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-9023","authenticated-orcid":false,"given":"David M.","family":"Koelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jtauto.2021.100114_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jtauto.2021.100114_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/ene.14951","article-title":"Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival","author":"Jakub\u00edkov\u00e1","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"9","key":"10.1016\/j.jtauto.2021.100114_bib3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14712598.2020.1786530","article-title":"Eculizumab for the treatment of myasthenia gravis","volume":"20","author":"Mantegazza","year":"2020","journal-title":"Expet Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.jtauto.2021.100114_bib4","article-title":"COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies","volume":"9","author":"Goldman","year":"2021","journal-title":"J. Immun. Canc."},{"issue":"8","key":"10.1016\/j.jtauto.2021.100114_bib5","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ccell.2021.06.015","article-title":"Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient","volume":"39","author":"Hill","year":"2021","journal-title":"Canc. Cell"},{"issue":"21","key":"10.1016\/j.jtauto.2021.100114_bib6","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"issue":"6541","key":"10.1016\/j.jtauto.2021.100114_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1126\/science.372.6541.443","article-title":"Relief and worry for immune-suppressed people","volume":"372","author":"Couzin-Frankel","year":"2021","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.jtauto.2021.100114_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00989-21","article-title":"Anti-SARS-CoV-2 antibody levels measured by the Advise Dx SARS-CoV-2 assay are concordant with previously available serologic assays but are not fully predictive of sterilizing immunity","author":"Bradley","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jtauto.2021.100114_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100114_bib10","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","author":"Furer","year":"2021","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909021000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909021000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:42:06Z","timestamp":1762904526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909021000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":10,"alternative-id":["S2589909021000344"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2021.100114","relation":{},"ISSN":["2589-9090"],"issn-type":[{"type":"print","value":"2589-9090"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2021.100114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100114"}}